By Fineline Cube 
Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced a licensing agreement with Intsel Chimos SAS, the French pharmaceutical distributor, granting exclusive commercialization rights for Ryzneuta (efbemalenograstim alfa, F-627) in France. The long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF) leverages Yifan’s proprietary Di-Kine bimolecular technology platform and is indicated for the prevention and treatment of chemotherapy-induced neutropenia in cancer patients.
Transaction Framework
| Item | Detail |
|---|---|
| Licensor | Yifan Pharmaceutical Co., Ltd. (SHE: 002019) |
| Licensee | Intsel Chimos SAS (France) |
| Asset | Ryzneuta (efbemalenograstim alfa, F-627) – rhG-CSF |
| Territory | Exclusive rights for France |
| Technology Platform | Proprietary Di-Kine bimolecular technology |
| Previous Partnerships | Vitalis Therapeutics Pty Ltd for Australia and New Zealand |
Product Profile & Innovation
- Molecule Type: Recombinant human G-CSF (rhG-CSF) with enhanced properties
- Technology Platform: Di-Kine bimolecular technology enabling long-lasting and potent biological characteristics
- Therapeutic Indication: Prevention and treatment of chemotherapy-induced neutropenia in cancer patients
- Mechanism: Leukopoietic agent stimulating neutrophil production and function
- Competitive Differentiation: Extended half-life potentially enabling less frequent dosing compared to standard G-CSF products
- Market Position: Biosimilar/biobetter positioning in established $5+ billion global G-CSF market
Strategic Significance
| Aspect | Details |
|---|---|
| European Market Entry | France represents gateway to broader European G-CSF market with established reimbursement pathways |
| Distribution Partnership | Leverages Intsel Chimos’ established hospital and oncology distribution network in France |
| Global Expansion Strategy | Part of systematic international rollout following Australian/New Zealand partnership |
| Technology Validation | International partnerships validate Yifan’s proprietary Di-Kine platform capabilities |
The agreement demonstrates Yifan’s successful strategy of partnering with regional specialists to access high-value markets while retaining manufacturing and technology control.
Market Impact & Outlook
- French G-CSF Market: Estimated €150–200 million annual market with strong demand from oncology centers
- Competitive Landscape | Established players include Amgen’s Neupogen/Neulasta and multiple biosimilars; differentiation through dosing convenience critical
- Regulatory Pathway | Likely approved via centralized EMA procedure or national French authorization based on existing approvals
- Revenue Potential | Estimated peak annual revenue of €20–30 million from French market opportunity
- Strategic Implications | Success in France may catalyze additional European partnerships and expand Yifan’s global footprint
Forward‑Looking Statements
This brief contains forward-looking statements regarding licensing agreements, regulatory pathways, market opportunities, and commercial expectations for Ryzneuta. Actual results may differ due to risks including regulatory decisions, competitive dynamics, market access challenges, and reimbursement negotiations.-Fineline Info & Tech